(HealthDay)—Self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) should be made available as an additional approach for contraception, according to research published in the May 21 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.